What happened
The FDA classified the Claria System as a Class II gynecologic power morcellator and containment system. Its authorized use is limited: tissue must be considered benign, and use in women with fibroids is restricted to premenopausal patients under 50.
Why it matters
Morcellation can enable minimally invasive surgery, but it has also raised serious safety concerns when unsuspected malignancy is present. An integrated containment approach is a material device-development milestone, not a removal of the underlying clinical risk.
What to watch
Post-market safety data, surgeon training, patient-selection practice, and whether integrated containment changes complication or conversion rates.
